| NeuroScientific Biopharmaceuticals Ltd (NSB) ORDINARY FULLY PAID |
Health Care |
$21 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 Oct 2026 9:08AM |
$0.052 |
$0.054 |
risen by
3.85%
|
|
NSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers the period ended 30 September 2026 and was announced on 27 October 2026.
- NSB’s main focus was progressing StemSmart™ toward a Phase 2 clinical trial in refractory Crohn’s disease in Australia and the United States.
- A US FDA pre-IND meeting was held during the quarter, with positive feedback announced after quarter end on 13 October 2026.
- The FDA confirmed the proposed Phase 2 trial design, supported 6 of 7 key questions, accepted the release-testing strategy, and did not require additional non-clinical studies.
- One remaining FDA matter related to StemSmart™ manufacturing testing strategy and was being implemented with minimal impact to timelines.
- Subsequent to quarter end, Southern Star Research was appointed on 1 October 2026 as the clinical trial partner for the planned Phase 2 trial.
- NSB remained on track to initiate the Phase 2 clinical trial for refractory Crohn’s disease by the end of calendar year 2026.
- The company continued planning an open-label early phase clinical trial in fistulising Crohn’s disease.
- StemSmart™ manufacturing technology transfer to Q-Gen Cell Therapeutics continued during the quarter and remained on schedule for completion in 2H CY2026, subject to validation and TGA audit.
- Validation activities included GMP engineering and demonstration runs and qualification of testing and control strategy for TGA review.
- Dr Catherine Cole presented StemSmart™ data and manufacturing information at the ISCT ANZ 2026 conference.
- Horizon Nexus (WA) Audit Pty Ltd resigned and In.Corp Audit & Assurance Pty Ltd was appointed as new auditor, with shareholder approval received on 15 October 2026.
- Shareholders approved the company name change to Miro Sciences Ltd, effective 28 October 2026.
- Cash and cash equivalents at 30 September 2026 were A$3.911 million.
- Net cash used in operating activities for the quarter was A$719,000.
- Quarterly cash outflows included A$409,000 for research and development, A$50,000 for advertising and marketing, A$69,000 for staff costs, and A$242,000 for administration and corporate costs.
- Related party payments totalled A$80,000 and related to director salaries, fees and superannuation.
- The Appendix 4C showed no investing or financing cash flows for the quarter and estimated 5.44 quarters of funding available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,353 |
Appendix 3Y Dr Christian Behrenbruch
|
27 Oct 2026 9:07AM |
$12.850 |
$12.790 |
fallen by
0.47%
|
|
| Saturn Metals Limited (STN) ORDINARY FULLY PAID |
Materials |
$305 |
Letter to Shareholders - Notice of AGM
|
27 Oct 2026 9:07AM |
$0.395 |
$0.405 |
risen by
2.53%
|
|
| Immuron Limited (IMC) ORDINARY FULLY PAID |
Health Care |
$12 |
Immuron FY27 Sales Update
|
27 Oct 2026 9:07AM |
$0.040 |
$0.037 |
fallen by
7.50%
|
|
IMC - Price-sensitive ASX Announcement
Full Release
Key Points
- Global Q1 FY27 sales were AUD$2.2 million, up 9% on the prior corresponding period and 5% on the prior quarter.
- Australian Q1 FY27 sales were AUD$1.8 million, up 14% year on year and 12% quarter on quarter.
- Australian sales growth was driven by the Travelan® relaunch, new packaging, brand communications and support from major pharmacy banner groups.
- Travelan® was described as one of the fastest growing anti-diarrhoeals and digestive health brands in pharmacy, with 26.4% growth versus category growth of 5.3%.
- PROIBS® expanded distribution through Sigma and became available in Amcal and DDS pharmacies.
- Canadian Q1 FY27 sales were AUD$0.1 million, up 286% on the prior corresponding period and 63% on the prior quarter.
- Canadian growth was attributed to increased brand awareness and product sampling at Shoppers Drug Mart conferences in Toronto and Calgary.
- July 2026 was Travelan’s highest non-pipeline sales month in Canada.
- U.S. Q1 FY27 sales were AUD$0.3 million, down 19% on the prior corresponding period and 24% on the prior quarter.
- The U.S. decline was attributed to stronger purchases during Amazon Prime Day in June 2026 and customs and logistics delays affecting inventory replenishment.
- Immuron said U.S. inventory had been replenished and noted a positive outlook for the next quarter due to Amazon Prime Days in October and Thanksgiving, Black Friday and Cyber Monday in November.
- The release also profiles Immuron’s broader product portfolio and platform, including Travelan®, IMM-529 and PROIBS®.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AKORA Resources Limited (AKO) ORDINARY FULLY PAID |
Materials |
$17 |
30 September 2026 Quarterly Activities & Cashflow Report
|
27 Oct 2026 9:07AM |
$0.078 |
$0.080 |
risen by
2.56%
|
|
AKO - Price-sensitive ASX Announcement
Full Release
Key Points
- AKORA continued to receive multiple credible strategic party interest in the Bekisopa Iron Ore Project with due diligence processes underway.
- Critical supply chain optimisation for Bekisopa progressed through logistics modelling, Toliara port site visits, route survey work and identification of an alternative regional haulage route.
- The company engaged several potential logistics partners for road haulage solutions for the planned Stage 1 DSO operation.
- Community programs at Bekisopa included solar water pump upgrades, reforestation nurseries, education initiatives, delivery of equipment and governance workshops.
- AKORA completed an equity raising, including entitlement offer shortfall and placement funds totalling A$1.7 million in July 2026.
- Bekisopa remains the flagship project, targeting Stage 1 production of up to 2 Mtpa of about 61.6% Fe DSO and later Stage 2 production of +67% Fe concentrate.
- The report cites Bekisopa’s inferred mineral resource of 194.7 Mt at 32.0% Fe and a probable ore reserve of 9.068 Mt at 53.0% Fe.
- No activities were completed at the Satrokala Project during the quarter as focus remained on Bekisopa.
- Cash at 30 September 2026 was approximately A$2.135 million.
- Quarterly exploration and evaluation expenditure was A$438,575, and there was no mine production or development activity during the quarter.
- Quarterly net cash used in operating activities was A$436,000 and in investing activities was A$439,000, while net cash from financing activities was A$738,000.
- AKORA estimated it had 2.4 quarters of funding available at quarter end.
- The report was dated 27 October 2026 and authorised by the board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sea Forest Limited (SEA) ORDINARY FULLY PAID |
Consumer Staple |
$72 |
2026 AGM Letter of Access, Notice of AGM and Proxy Form
|
27 Oct 2026 9:07AM |
$1.530 |
$1.530 |
fallen by
0%
|
|
| Connected Minerals Limited (CML) ORDINARY FULLY PAID |
Information Technology |
$45 |
Extensive High-Grade Mineralisation in Historical Data
|
27 Oct 2026 9:06AM |
$0.360 |
$0.335 |
fallen by
6.94%
|
|
CML - Price-sensitive ASX Announcement
Full Release
Key Points
- Connected Minerals acquired the historical exploration database for the Bailundo Carbonatite Project through its Angolan subsidiary Frontier Resources Angola.
- The historical dataset covers about 39km² and includes mapping, soil and rock-chip sampling, drill logs, assays, core photographs and technical studies.
- Historical drilling comprised 10 diamond holes for 3,414.4m, with only six holes assayed.
- Standout niobium drilling result was 205.5m @ 1.0% Nb2O5 from surface in hole SB02, including 24.0m @ 3.0% Nb2O5.
- Standout rare earth drilling result was 227.3m @ 2.0% TREO from surface in hole SB06, within a broader 358.9m @ 1.7% TREO interval.
- Other strong rare earth intersections included 121.3m @ 2.4% TREO in SB03 and 201.8m @ 1.8% TREO in SB04.
- The data defines a Central/Southern niobium target and a Northern rare earth target across the Bailundo complex.
- Mineralisation occurs in weathered saprolite and saprock as well as underlying less-weathered to fresh carbonatite.
- About 1,534m of historical drilling remains unassayed, including four entire holes, providing further upside for niobium, rare earths and gallium.
- Historical drill assays identified gallium values up to 167.5ppm in hole SB04, associated with weathered mineralised material.
- Surface geochemistry includes 1,089 soil samples and 458 rock-chip samples with broad high-grade anomalies.
- Historical soil results included 118 samples at or above 0.5% Nb2O5 with a peak of 1.43% Nb2O5.
- Historical soil results included 339 samples at or above 1.5% TREO with a peak of 3.36% TREO.
- Some historical niobium and rare earth assays reached upper analytical reporting limits, meaning certain reported values may be minimums.
- CML plans to integrate the historical data with current drilling, geological modelling, mineralogical characterisation and metallurgical investigations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,365 |
Update - Notification of buy-back - AFI
|
27 Oct 2026 9:05AM |
$6.770 |
$6.820 |
risen by
0.74%
|
|
| Centuria Capital Group (CNI) STAPLED SEC EXCL US INVESTOR PROHIBITED EXCL QPS |
Real Estate |
$1,124 |
Appendix 4G and Corporate Governance Statement
|
27 Oct 2026 9:05AM |
$1.110 |
$1.120 |
risen by
0.90%
|
|
| Region Group (RGN) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$2,604 |
Update - Notification of buy-back - RGN
|
27 Oct 2026 9:05AM |
$2.270 |
$2.270 |
fallen by
0%
|
|
| Astron Corporation Limited (ATR) ORDINARY FULLY PAID |
Materials |
$258 |
Trading Halt
|
27 Oct 2026 9:05AM |
$0.615 |
$0.600 |
fallen by
2.44%
|
|
ATR - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Astron Limited (ASX: ATR) into a trading halt at the company’s request.
- The trading halt was pending a material market announcement by Astron.
- Astron said the pending announcement related to a proposed project financing.
- ASX stated the halt would last until the earlier of the announcement being released or normal trading commencing on Thursday, 29 October 2026.
- Astron stated it was not aware of any reason the trading halt should not be granted.
- The attached request letter contains date inconsistencies compared with the ASX announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Symal Group Limited (SYL) ORDINARY FULLY PAID |
Industrials |
$605 |
2026 Notice of Annual General Meeting
|
27 Oct 2026 9:04AM |
$2.510 |
$2.530 |
risen by
0.80%
|
|
| Bougainville Copper Limited (BOC) 1 KINA ORDINARY FULLY PAID |
Materials |
$44 |
Reinstatement to Quotation
|
27 Oct 2026 9:04AM |
$0.160 |
$0.110 |
fallen by
31.25%
|
|
| L1 Global Long Short Fund Limited (GLS) ORDINARY FULLY PAID |
Financials |
$1,163 |
Results of successful equity raising of approximately $565m
|
27 Oct 2026 9:03AM |
$1.870 |
$1.920 |
risen by
2.67%
|
|
GLS - Price-sensitive ASX Announcement
Full Release
Key Points
- GLS announced the successful completion of an equity raising totalling approximately A$565.4 million.
- The capital raising included institutional and retail entitlement offers, shortfall offers, and a placement.
- The previously completed institutional entitlement and shortfall offers raised approximately A$100.9 million through 57.3 million new shares.
- The retail entitlement offer, including the top-up facility, raised approximately A$177.2 million through about 100.7 million new shares at A$1.76 each.
- The retail shortfall offer raised approximately A$204.5 million through about 116.2 million new shares and was oversubscribed.
- The placement raised approximately A$82.7 million through about 47.0 million new shares at the same offer price.
- A total of 321,248,063 new shares will be issued under the equity raising.
- New shares are expected to be allotted on 30 October 2026 and commence normal ASX trading on 2 November 2026.
- Proceeds will be invested in line with the L1 Global Long Short Strategy.
- L1 Capital Pty Ltd will bear all costs associated with the equity raising.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$544 |
Weekly NTA 23 October 2026
|
27 Oct 2026 9:02AM |
$1.975 |
$1.945 |
fallen by
1.52%
|
|
| Kingsrose Mining Limited (KRM) ORDINARY FULLY PAID |
Materials |
$14 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
27 Oct 2026 9:02AM |
$0.019 |
$0.019 |
fallen by
0%
|
|
KRM - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report and Appendix 5B cover the period ended 30 September 2026 and were authorised on 27 October 2026.
- Penikat Area 6 in Finland received an Exploration Permit and Enforcement Order from Tukes.
- The Penikat permit allows up to 5,000m of drilling between 1 August and 31 March across successive years.
- Appeals on the Penikat Exploration Permit and Enforcement Order were open until 20 November 2026.
- Kingsrose is targeting initial drilling at Penikat Area 6 in January 2027.
- Finnmark fieldwork covered 15 Cu-Ni-PGE targets and 5 orogenic gold targets.
- Kingsrose collected 804 ionic leach soil samples over 142 line-kilometres and 43 rock chip samples at Finnmark.
- Finnmark assay results were expected in late 2026 to support target refinement and future geophysics.
- Kingsrose reported strong support from Sámi rightsholders and municipalities for summer field activities in Finnmark.
- Norway’s revised Minerals Act extended exploration licence duration and is expected to streamline future drill permitting.
- Kingsrose was advancing discussions with potential strategic partners to fund accelerated exploration at Finnmark.
- No exploration activity was conducted at Penikat during the quarter while drill permitting advanced.
- No exploration activity was conducted at the Råna Project during the quarter.
- After quarter end, Kingsrose amended the EMX option terms at Råna, extending the A$1.0 million cumulative spend deadline to 1 September 2028.
- The amended Råna terms also require defined drill targets of at least 1,000m by 1 September 2028 and completion of at least 1,000m of drilling by 1 September 2029.
- Project expenditure during the quarter was A$486,000 at Finnmark, A$37,000 at Penikat and A$68,000 at Råna.
- Kingsrose held A$16.718 million in cash and cash equivalents at 30 September 2026.
- Net cash used in operating activities for the quarter was A$1.341 million.
- Exploration and evaluation payments in the Appendix 5B were A$630,000 for the quarter.
- Administration and corporate cash payments were A$616,000 and interest received was A$207,000.
- Financing cash outflow of A$36,000 related to repayment of hire purchases or leased right-of-use assets.
- Related party payments of A$62,000 were paid to directors’ salaries and fees.
- The company estimated it had funding for 12 quarters based on current cash outflows.
- James Withall was appointed Non-Executive Director on 24 August 2026.
- Andy Caruso was appointed Managing Director on 16 October 2026.
- Kingsrose had 753,526,519 ordinary shares and 10,500,000 options on issue at 30 September 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kingsgate Consolidated Limited (KCN) ORDINARY FULLY PAID |
Materials |
$1,116 |
Plant 1 Insurance Claim Update
|
27 Oct 2026 9:00AM |
$4.080 |
$4.190 |
risen by
2.70%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$282 |
Update - Notification of buy-back - RG8
|
27 Oct 2026 8:59AM |
$2.000 |
$2.010 |
risen by
0.50%
|
|
| Culpeo Minerals Limited (CPO) ORDINARY FULLY PAID |
Materials |
$10 |
IMARC Conference Presentation
|
27 Oct 2026 8:59AM |
$0.012 |
$0.012 |
fallen by
0%
|
|
| Dexus Industria REIT (DXI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$728 |
Update - Notification of buy-back - DXI
|
27 Oct 2026 8:59AM |
$2.390 |
$2.360 |
fallen by
1.26%
|
|
| Nimy Resources Limited (NIM) ORDINARY FULLY PAID |
Materials |
$11 |
Quarterly Activities and Cashflow Statement
|
27 Oct 2026 8:58AM |
$0.034 |
$0.032 |
fallen by
5.88%
|
|
NIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Corporate James East was defined as a third major gold anomaly on the approximately 16km Corporate James Trend.
- The northern Corporate James East sample line was anomalous ????? its full 950m length, with all 20 samples returning at least 9.6 ppb Au and a peak of 21.3 ppb Au.
- The Corporate James East anomaly remains open to the east and follow-up sampling is underway, while drilling at Corporate James commenced in mid-October 2026.
- A total of 4,594 Ultrafine soil samples across Masson, Masson NE and Thompson outlined three parallel gold trends and identified a large potential VHMS-style Cu-Zn-Ag mineralised area at Masson NE.
- Ground EM surveys designed by Newexco commenced across Masson, Masson NE, Sneaky Squirrel and Block 3 to define drill targets linked to sulphide mineralisation.
- At Block 3, early metallurgical sighter testwork delivered 84% gallium extraction and 80–95% rare earth extraction, with acid bake giving the highest extraction results.
- The MRIWA–Nimy–Curtin–Trailblazer gallium processing research project commenced and its work is feeding into the Block 3 Gallium Scoping Study.
- The company reported cash and cash equivalents of A$2.257 million at 30 September 2026.
- Quarterly cash flows showed net operating outflow of A$563,000, net investing outflow of A$1.074 million and net financing outflow of A$26,000.
- Exploration and evaluation cash expenditure for the quarter was A$1.011 million, including sample testing, geophysics, labour, wages, rent and tenement costs.
- Related party payments totalled A$191,000, comprising A$128,000 in director fees and A$63,000 in rental charges.
- Nimy estimated 1.43 quarters of funding available at quarter end and stated it could scale discretionary spending and access further capital under existing ASX placement capacities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,852 |
Update - Notification of buy-back - ORA
|
27 Oct 2026 8:58AM |
$1.515 |
$1.515 |
fallen by
0%
|
|
| Dexus Convenience Retail REIT (DXC) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$368 |
Update - Notification of buy-back - DXC
|
27 Oct 2026 8:58AM |
$2.770 |
$2.740 |
fallen by
1.08%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$28 |
Peer-Reviewed Study Reports 100% Disease Control
|
27 Oct 2026 8:57AM |
$0.700 |
$0.750 |
risen by
7.14%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$554 |
Update - Notification of buy-back - RG1
|
27 Oct 2026 8:57AM |
$2.390 |
$2.390 |
fallen by
0%
|
|
Call 1300 880 160
Start a chat
Schedule a call
